Annual Financials for Eli Lilly & Co.
Fiscal year is January-December. All values USD millions. |
2016 | 2017 | 2018 | 2019 | 2020 |
5-year trend |
Sales/Revenue
|
21.22B | 22.87B | 21.49B | 22.32B | 24.54B | |
Sales Growth |
- | 7.77% | -6.03% | 3.84% | 9.95% | |
Cost of Goods Sold (COGS) incl. D&A |
5.65B | 6.07B | 4.68B | 4.72B | 5.48B | |
COGS excluding D&A |
4.16B | 4.5B | 3.07B | 3.49B | 4.16B | |
Depreciation & Amortization Expense |
1.5B | 1.57B | 1.61B | 1.23B | 1.32B | |
Depreciation |
808.7M | 883.9M | 1.25B | 1.01B | 895.7M | |
Amortization of Intangibles |
687.9M | 683.4M | 361.3M | 225.8M | 428.2M | |
COGS Growth |
- | 7.34% | -22.87% | 0.84% | 16.14% | |
Gross Income |
15.57B | 16.8B | 16.81B | 17.6B | 19.06B | |
Gross Income Growth |
- | 7.93% | 0.06% | 4.68% | 8.29% | |
Gross Profit Margin |
- | - | - | - | 77.66% | NA |
|
2016 | 2017 | 2018 | 2019 | 2020 |
5-year trend |
SG&A Expense |
11.7B | 11.87B | 11.03B | 11.81B | 12.21B | |
Research & Development |
5.24B | 5.28B | 5.05B | 5.6B | 6.09B | |
Other SG&A |
6.45B | 6.59B | 5.98B | 6.21B | 6.12B | |
SGA Growth |
- | 1.49% | -7.11% | 7.10% | 3.37% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
590.6M | 2.88B | 2.15B | 1.02B | 565.5M | |
EBIT after Unusual Expense |
3.28B | (2.88B) | (2.15B) | 4.77B | 6.28B | |
Non Operating Income/Expense |
169.8M | 208M | 128.8M | 819.5M | 1.27B | |
Non-Operating Interest Income |
108.7M | 167.3M | 159.3M | 80.4M | 33M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
185.2M | 225M | 242.5M | 400.6M | 359.6M | |
Interest Expense Growth |
- | 21.49% | 7.78% | 65.20% | -10.23% | |
Gross Interest Expense |
232.9M | 282.3M | 242.5M | 400.6M | 359.6M | |
Interest Capitalized |
47.7M | 57.3M | - | - | - | |
Pretax Income |
3.37B | 2.2B | 3.68B | 5.27B | 7.23B | |
Pretax Income Growth |
- | -34.87% | 67.48% | 43.09% | 37.30% | |
Pretax Margin |
- | - | - | - | 29.46% | NA |
Income Tax |
636.4M | 2.4B | 529.5M | 628M | 1.04B | |
Income Tax - Current Domestic |
(182M) | 3.15B | 174.3M | 265.8M | 520.3M | |
Income Tax - Current Foreign |
378.9M | 38.5M | 106.8M | 299.8M | 650.4M | |
Income Tax - Deferred Domestic |
522.8M | (531.6M) | (300,000) | 86.5M | (117.9M) | |
Income Tax - Deferred Foreign |
(83.3M) | (256.3M) | 248.7M | (24.1M) | (16.6M) | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
2.74B | (204.1M) | 3.15B | 4.64B | 6.19B | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
2.74B | (204.1M) | 3.15B | 4.64B | 6.19B | |
Net Income Growth |
- | -107.46% | 1,643.66% | 47.21% | 33.55% | |
Net Margin Growth |
- | - | - | - | 25.24% | NA |
Extraordinaries & Discontinued Operations |
- | - | 81.4M | 3.68B | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | 81.4M | 3.68B | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
2.74B | (204.1M) | 3.23B | 8.32B | 6.19B | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
2.74B | (204.1M) | 3.15B | 4.64B | 6.19B | |
EPS (Basic) |
2.59 | (0.19) | 3.07 | 4.98 | 6.82 | |
EPS (Basic) Growth |
- | -107.34% | 1,713.47% | 62.49% | 36.99% | |
Basic Shares Outstanding |
1.06B | 1.05B | 1.03B | 931.06M | 907.63M | |
EPS (Diluted) |
2.58 | (0.19) | 3.05 | 4.96 | 6.79 | |
EPS (Diluted) Growth |
- | -107.36% | 1,704.21% | 62.62% | 36.94% | |
Diluted Shares Outstanding |
1.06B | 1.05B | 1.03B | 935.68M | 912.51M | |
EBITDA |
5.37B | 6.5B | 7.39B | 7.02B | 8.17B | |
EBITDA Growth |
- | 21.06% | 13.78% | -5.03% | 16.40% | |
EBITDA Margin |
- | - | - | - | 33.31% | NA |